{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:45:08Z","timestamp":1790261108077,"version":"4.1.0"},"reference-count":50,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T00:00:00Z","timestamp":1691366400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007605","name":"Aarhus Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007605","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To examine disparities in glucose\u2010lowering drug (GLD) usage between migrants and native Danes with type 2 diabetes (T2D).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>In a nationwide, register\u2010based cross\u2010sectional study of 253\u2009364 individuals with prevalent T2D on December 31, 2018, we examined user prevalence during 2019 of (i) GLD combination therapies and (ii) individual GLD types. Migrants were grouped by origin (Middle East, Europe, Turkey, Former Yugoslavia, Pakistan, Sri Lanka, Somalia, Vietnam), and relative risk (RR) versus native Danes was computed using robust Poisson regression to adjust for clinical and socioeconomic characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 2019, 34.7% of native Danes received combination therapy, and prevalence was lower in most migrant groups (RR from 0.78, 95% confidence interval CI 0.71\u20100.85 [Somalia group] to 1.00, 95% CI 0.97\u20101.04 [former Yugoslavia group]). Among native Danes, the most widely used oral GLD was metformin (used by 62.1%), followed by dipeptidyl peptidase\u20104 inhibitors (13.3%), sodium\u2010glucose cotransporter\u20102 inhibitors (11.9%) and sulphonylureas (5.2%), and user prevalence was higher in most migrant groups (RR for use of any oral GLD: 0.99, 95% CI 0.97\u20101.01 [Europe group] to 1.09, 95% CI 1.06\u20101.11 [Sri Lanka group]). Furthermore, 18.7% of native Danes used insulins and 13.3% used glucagon\u2010like peptide\u20101 receptor agonists (GLP\u20101RAs), but use was less prevalent in migrants (RR for insulins: 0.66, 95% CI 0.62\u20100.71 [Sri Lanka group] to 0.94, 95% CI 0.89\u20100.99 [Europe group]; RR for GLP\u20101RAs: 0.29, 95% CI 0.22\u20100.39 [Somalia group] to 0.95, 95% CI 0.89\u20101.01 [Europe group]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Disparities in GLD types and combination therapy were evident between migrants and native Danes. Migrants were more likely to use oral GLDs and less likely to use injection\u2010based GLDs, particularly GLP\u20101RAs, which may contribute to complication risk and mortality among this group.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.15230","type":"journal-article","created":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T00:50:26Z","timestamp":1691455826000},"page":"3307-3316","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Glucose\u2010lowering drug use in migrants and native\n                    <scp>Danes<\/scp>\n                    with type 2 diabetes: Disparities in combination therapy and drug types"],"prefix":"10.1111","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8457-5466","authenticated-orcid":false,"given":"Anders Aasted","family":"Isaksen","sequence":"first","affiliation":[{"name":"Department of Public Health Aarhus University  Aarhus Denmark"},{"name":"Steno Diabetes Center Aarhus Aarhus University Hospital  Aarhus N Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelli","family":"Sandb\u00e6k","sequence":"additional","affiliation":[{"name":"Department of Public Health Aarhus University  Aarhus Denmark"},{"name":"Steno Diabetes Center Aarhus Aarhus University Hospital  Aarhus N Denmark"},{"name":"Research Unit for General Practice  Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette Vinther","family":"Skriver","sequence":"additional","affiliation":[{"name":"Department of Public Health Aarhus University  Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lasse","family":"Bjerg","sequence":"additional","affiliation":[{"name":"Department of Public Health Aarhus University  Aarhus Denmark"},{"name":"Steno Diabetes Center Aarhus Aarhus University Hospital  Aarhus N Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,8,7]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14476"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2016.04.037"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13694"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2007.07.007"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen\u20102018\u2010023211"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472\u20106963\u201010\u2010145"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083292"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen\u20102015\u2010007599"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003106"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2013.09.012"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(19)31149\u20103"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.032038"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci22\u20100034"},{"key":"e_1_2_8_19_1","unstructured":"Farmakologisk behandling af hyperglyk\u00e6mi.2022Available fromhttps:\/\/vejledninger.dsam.dk\/fbv\u2010t2dm\/?mode=visKapitel&cid=1487&gotoChapter=1490"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.316.7125.100"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc\u20102022\u2010002867"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.110233"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002942"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125\u2010020\u201005304\u20103"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2021.100111"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13830"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2022.100308"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.13885"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14947"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14874"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.2147\/clep.S179083"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654\u2010014\u20109930\u20103"},{"key":"e_1_2_8_33_1","unstructured":"Eurostat Glossary: Equivalised disposable income. Available fromhttps:\/\/ec.europa.eu\/eurostat\/statistics-explained\/index.php?title=Glossary:Equivalised_disposable_income. Accessed Jan 11 2023"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.2147\/clep.S91125"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyw213"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/1403494810394718"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.2147\/clep.S407019"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.21\u20100665"},{"key":"e_1_2_8_39_1","unstructured":"SinghammerJ.Etniske minoriteters sundhed (Health among ethnic minorities).2008."},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f7450"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179546"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14865"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14894"},{"key":"e_1_2_8_44_1","doi-asserted-by":"crossref","unstructured":"DorA EncinosaW.How does cost\u2010sharing affect drug purchases? Insurance regimes in the private market for prescription drugs. National Bureau of Economic Research Working Paper Series No. 10738.2004. doi:10.3386\/w10738","DOI":"10.3386\/w10738"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1557(199611)5:6<385::AID-PDS246>3.0.CO;2-8"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464\u20105491.2008.02538.x"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1177\/0145721712437559"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/ewjm.175.5.307"},{"key":"e_1_2_8_49_1","unstructured":"Dowle M Srinivasan A.data.table: Extension of \u2018data.frame\u2019. 2023.https:\/\/r-datatable.com"},{"key":"e_1_2_8_50_1","unstructured":"R Core Team.R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2023.https:\/\/www.R-project.org\/"},{"key":"e_1_2_8_51_1","unstructured":"RStudio Team.RStudio: Integrated Development Environment for R. RStudio PBC; 2022.http:\/\/www.rstudio.com\/"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.15230","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:40:00Z","timestamp":1761871200000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.15230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,7]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1111\/dom.15230"],"URL":"https:\/\/doi.org\/10.1111\/dom.15230","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,7]]},"assertion":[{"value":"2023-03-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}